Stopping vs. Continuing Metformin in Patients With Advanced CKD: A Nationwide Scottish Target Trial Emulation Study ca. 2025 from @ajkd.bsky.social
#Nephpearls #NephJC #NephSky
#VisualAbstract by @nephroseeker.medsky.social

👉 pubmed.ncbi.nlm.nih.gov/39521399/

Sparsentan as First-Line Treatment of Incident Patients with IgAN: Interim Analysis of the SPARTAN Trial
#Nephpearls #NKFClinicals 🇺🇸 #NephSky

📌 The rapid reduction of u-sCD163 levels is the first demonstration of SPAR’s anti-inflammatory effect in humans and supports preclinical data